![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Glaucoma afflicts tens of millions worldwide and is a leading cause of irreversible blindness. The primary objective in managing glaucoma is the reduction of elevated intraocular pressure. Bypassing outflow resistance at the level of the trabecular meshwork can re-establish physiologic aqueous humor outflow from the anterior chamber, thus reducing intraocular pressure. The iStent® trabecular micro-bypass stent is implanted directly into Schlemm’s canal through a clear corneal incision as a standalone procedure or in conjunction with cataract surgery to facilitate aqueous outflow through Schlemm’s canal. iStent is a minimally invasive alternative to current treatments for patients with open-angle glaucoma and has also been shown to offer distinct clinical advantages in the early stages of the disease.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.